No abstract

Purpose:To compare the effects of preoperative use of topical anti-inflammatory prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery.Design:Randomized clinical trial.Materials and Methods:This single-center, masked, randomized clinical study comprised 140 patients scheduled for cataract surgery. Patients (35 in each group) were randomized to receive placebo, prednisolone acetate, ketorolac tromethamine 0.4% or nepafenac. These eye drops were administered three times daily for the two days prior to surgery. The pupillary diameters were measured by the surgeon using a compass prior to the corneal section and at the end of surgery. The primary outcome was the number of patients with pupil ≥ 6mm at the end of the surgery; the secondary outcome was the number of patients with pupil ≥ 6mm at the beginning of the surgery.Results:All the patients achieved pupil ≥ 6mm at the beginning of the surgery. The number of patients in the prednisolone (29/35), nepafenac (31/35) and ketorolac (30/35) groups with pupil ≥ 6mm was greater than in the placebo group in the maintenance of intraoperative mydriasis (19/35 – P =0.003). There was no statistical difference among the prednisolone, nepafenac and ketorolac groups in the maintenance of intraoperative mydriasis (P =.791). There were no complications during surgery or related to the preoperative use of the eye drops.Conclusion:Preoperative use of ketorolac, prednisolone and nepafenac was effective in maintaining intraoperative mydriasis when compared with placebo.

Objective: To investigate if E-learning material improves the basal student knowledge level before attending the presential class of blindness prevention (BP) and if helps to fix this information one-month RESUMOObjetivo: Avaliar se um material disponibilizado através de E-learning antes de aulas presenciais de prevenção da cegueira (PC) melhora o nível de conhecimento basal dos estudantes, e ajuda a manter esse conteúdo um mês após a aula. Métodos: Estudantes do quarto ano do curso médico foram aleatoriamente sorteados para ter aulas presenciais de PC (grupo tradicional = GT) ou ter aulas presenciais precedidas de material adicional por E-learning (grupo E-learning = GEL). Este material foi enviado por correio eletrônico uma semana antes da aula presencial. Os estudantes foram submetidos a testes de múltipla escolha com sete questões (com três alternativas cada) imediatamente antes da aula presencial, imediatamente após a aula, e um mês após a aula. Os três testes tiveram as mesmas questões: entretanto, as respostas foram distribuídas em sequências diferentes. O desfecho primário foi a nota do pré-teste. Os desfechos secundários foram as notas dos pós-teste imediato e do pós-teste tardio. Resultados: Entre os 120 alunos do quarto ano de medicina, uma amostra aleatória de 34 alunos foi selecionada para o grupo GT e 34 alunos para o grupo GEL. Os dois grupos obtiveram nota similar no pós-teste imediato (GT=6.8 e GEL=6.9; P<.754), porém diferenças estatisticamente significativas no pré-teste (GT=3.6 e GEL=4.7; P<.001), e no pós-teste tardio (GT=6.1 e GEL=6.8; P<.001). Conclusão: Os resultados do pré-teste e do pós-teste tardio sugerem que o E-learning pode ser um complemento eficiente do ensino presencial de prevenção da cegueira.

Background: Endothelial dysfunction (ED) is a hallmark in type 2 diabetes mellitus (T2DM) that favor both atherogenesis and ischemia and reperfusion injury (IRI). Sodium-glucose-2 co-transporter inhibitors (SGLT2i) may hypothetically improve microvascular and macrovascular functions via a broad spectrum of mechanisms, being superior to traditional antidiabetic therapy such as sulfonylurea, even in subjects under equivalent glycemic control. Hence, the present clinical trial was designed to compare the effect of these two treatments on markers of arterial wall function and inflammation in T2DM patients as well as on the potential mediating parameters. Method and results: ADDENDA-BHS2 is a prospective, single-center, active-controlled, open, randomized trial. Ninety-eight participants (40-70 years old) with HbA1c 7-9% were randomized (1:1, stratified by gender, BMI and HbA1c levels) to either dapagliflozin 10 mg/day or glibenclamide 5 mg/day on top of metformin. The primary endpoint was the change of flow-mediated dilation (FMD) after a 12-week period of treatment evaluated at rest and after IRI between dapagliflozin and glibenclamide arms. Secondary outcomes were defined as the difference between treatments regarding: plasma nitric oxide (NO) change after FMD, plasma isoprostane, plasma levels of vascular inflammatory markers and systemic inflammatory markers, plasma levels of adipokines, anthropometric measures, glucose control parameters, office and ambulatory BP control. Safety endpoints were defined as systolic and diastolic function assessed by echocardiography and retinopathy change. Serious adverse events were recorded. The study protocol was approved by the Independent Scientific Advisory Committee. Conclusion: The ADDENDA-BHS2 trial is an investigator-initiated clinical trial comparing the effect of dapagliflozin versus glibenclamide on several aspects of vascular function in high cardiovascular risk T2DM patients. Besides, a large clinical and biochemical phenotype assessment will be obtained for exploring potential mediations and associations.

No abstract